Y-Intercept (HK)’s Ovid Therapeutics OVID Stock Holding History

Y-Intercept (HK)’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-160,306	Closed	-$52.9K	–	1917
2025 Q2	$52.9K	Buy	+160,306	New	+$48.3K	﹤0.01%	1556
2023 Q2	–	Sell	-35,116	Closed	-$90.6K	–	1596
2023 Q1	$90.6K	Buy	+35,116	New	+$83.2K	0.01%	1063
2021 Q3	–	Sell	-12,375	Closed	-$48K	–	841
2021 Q2	$48K	Buy	+12,375	New	+$48.8K	0.01%	560

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Y-Intercept (HK)'s OVID Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 160,306 shares — an estimated $52.9K sold.

Y-Intercept (HK) first reported a position in OVID in Q2 2021 and held it in 3 quarters. The position peaked at $90.6K in Q1 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Y-Intercept (HK) reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 160,306 Ovid Therapeutics shares in Q3 2025, an estimated $52.9K.
Y-Intercept (HK) first reported a position in Ovid Therapeutics in Q2 2021 and held it in 3 quarters.
Y-Intercept (HK)'s Ovid Therapeutics position peaked at $90.6K in Q1 2023.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.